Bristol-Myers Squibb’s (BMY) Neutral Rating Reiterated at The Goldman Sachs Group
The Goldman Sachs Group reiterated their neutral rating on shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The Goldman Sachs Group currently has a $55.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $67.00. Other equities […]
The Goldman Sachs Group reiterated their neutral rating on shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The Goldman Sachs Group currently has a $55.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $67.00. Other equities […]
